中外健康文摘
中外健康文摘
중외건강문적
WORLD HEALTH DIGEST
2012年
51期
6-8
,共3页
human papillomavirus type 18(HPV18)%E2%IL-12%vaccine
Objective:To study the effectiveness of human papillomavirus type 18 E2 gene (HPV18-E2) vaccine and interleukin-12(IL-12) on their immune effects. Methods:Thirty-five Balb/c female mice aged 6-8-week-old were randomly divided into five groups (each n =7).The mice were given instramuscular injection of DNA vaccines at 2-week four 4 times(100mg/time).The tails were cut to draw blood at the 0,2,4,6 weeks,and then the mice were executed by eyeball blood letting at 8 weeks.ELISA was used for the quantitative detection of the specific lgG antibody in the srea of Balb/c mice and the cytokine IFN-γ and IL-4 in mice MTT assay.Results: after 8 weeks immunization, antibody IgA in E2 vaccine group andE2 +IL-12 vaccine group was statistically increased as compared with that of control group, and the difference was statistically significant (P<0.01). IFN-γand IL-4 levels of mice spleen lymphocyte culture supernatant inE2 group and E2 + IL-12 were significantly higher than other control groups (P<0.01). the spleen lymphopoiesis activeness of E2 + IL-12 group was significant enhanced as compared with the E2 group, there were statistically significant differences (P<0.01) . Conclusions: E2 DNA vaccine combined with IL-12 immune mice can effectively induce cell-mediated immunity and humoral immune responses, their capabilities of inducing immune response might be more stronger than that of single one.